Prognostic risk‐stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012
- 15 April 2016
- journal article
- hemapheresis
- Published by Wiley in Transfusion
- Vol. 56 (6), 1451-1458
- https://doi.org/10.1111/trf.13586
Abstract
BACKGROUND Despite proven efficacy and increased availability of therapeutic plasma exchange (TPE), mortality for patients with thrombotic thrombocytopenic purpura (TTP) remains high with a limited understanding of those at highest risk of death. STUDY DESIGN AND METHODS This study utilized the Nationwide Inpatient Sample (2007‐2012) to derive a prognostic score for mortality in hospitalized TTP patients. Odds ratios of death with various putative risk factors adjusted for age, sex, and race were calculated (adjOR). Weighted mean of adjOR estimates were incorporated in a risk‐stratified score. RESULTS Among 8203 hospitalizations with TTP as primary admission diagnosis who underwent TPE, 613 deaths were identified (all‐cause mortality, 7.5%; median time‐to‐death, 9 days; interquartile range, 4‐14 days). In multivariable logistic regression, arterial thrombosis (adjOR 6.7, 95% confidence interval [CI], 1.1‐40.9), intracranial hemorrhage (adjOR, 6.1; 95% CI, 1.6‐23.2), age at least 60 years (adjOR, 3.5; 95% CI, 2.1‐5.6), renal failure (adjOR, 2.6; 95% CI, 1.5‐4.5), ischemic stroke (adjOR, 2.4; 95% CI, 1.2‐5.0), platelet (PLT) transfusions (adjOR, 2.2; 95% CI, 1.2‐4.1), and myocardial infarction (adjOR, 2.3; 95% CI, 1.2‐4.6) were significant independent predictors of mortality in TTP patients who underwent TPE. A prognostic weighted mortality prediction scoring system incorporating arterial thrombosis, intracranial hemorrhage, age, renal failure, ischemic stroke, PLT transfusion, and myocardial infarction showed very good discrimination and was predictive of 78.6% deaths. CONCLUSIONS Early and targeted therapy for high‐risk individuals should be used to guide management of TTP patients for improved survival outcomes.Keywords
Funding Information
- National Institutes of Health (1K23AI093152-01A1)
This publication has 38 references indexed in Scilit:
- The Oklahoma thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome RegistryHamostaseologie, 2013
- Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experienceHaematologica, 2012
- How I approach a thrombotic thrombocytopenia purpura patientTransfusion, 2006
- Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchangeBritish Journal of Haematology, 2005
- Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accidentJournal of Clinical Apheresis, 2004
- Recent Advances in Thrombotic Thrombocytopenic PurpuraHematology-American Society Hematology Education Program, 2004
- Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991American Journal of Hematology, 1995
- Improved Survival in Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic SyndromeNew England Journal of Medicine, 1991
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991
- Thrombotic Thrombocytopenic PurpuraMedicine, 1981